CLINICAL TRIALS PROFILE FOR SAQUINAVIR MESYLATE

All Clinical Trials for Saquinavir Mesylate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001040 ↗	Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC	Completed	Hoffmann-La Roche	Phase 2	1969-12-31	PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC) vs. Ro 31-8959 plus AZT plus ddC. SECONDARY: To investigate the pharmacokinetics and effects on various clinical parameters of the three regimens.
NCT00002111 ↗	A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.	Completed	Stanford University	Phase 1	1969-12-31	To investigate the toxicity, antiviral activity, and pharmacokinetics in HIV-infected patients receiving 16 weeks of oral saquinavir mesylate ( Ro 31-8959 ) at one of two doses.
NCT00002333 ↗	A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine	Completed	Hoffmann-La Roche	Phase 2	1969-12-31	To compare the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone, zalcitabine (dideoxycytidine; ddC) alone, and both in combination, in patients discontinuing or unable to take zidovudine (AZT).
NCT00002334 ↗	A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment	Completed	Hoffmann-La Roche	Phase 3	1969-12-31	To compare, in zidovudine (AZT)-naive patients, the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone versus AZT alone versus AZT in combination with Ro 31-8959, zalcitabine (ddC), or both. To compare various disease markers among the different regimens.
NCT00003008 ↗	Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma	Completed	AIDS Associated Malignancies Clinical Trials Consortium	Phase 2	1997-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with AIDS-related Kaposi's sarcoma.
NCT00003008 ↗	Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma	Completed	National Cancer Institute (NCI)	Phase 2	1997-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with AIDS-related Kaposi's sarcoma.
NCT00003008 ↗	Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma	Completed	Eastern Cooperative Oncology Group	Phase 2	1997-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with AIDS-related Kaposi's sarcoma.

Clinical Trial Conditions for Saquinavir Mesylate

Condition Name

Condition Name for Saquinavir Mesylate
Intervention	Trials
HIV Infections	6
Saquinavir/Ritonavir BID or Lopinavir/Ritonavir BID	1
Sarcoma	1

Condition MeSH

Condition MeSH for Saquinavir Mesylate
Intervention	Trials
HIV Infections	6
Acquired Immunodeficiency Syndrome	2
Sarcoma, Kaposi	1
Sarcoma	1

Clinical Trial Locations for Saquinavir Mesylate

Trials by Country

Trials by Country for Saquinavir Mesylate
Location	Trials
United States	52
Canada	4
Puerto Rico	3

Trials by US State

Trials by US State for Saquinavir Mesylate
Location	Trials
California	5
Ohio	4
New York	4
Massachusetts	4
Texas	3

Clinical Trial Progress for Saquinavir Mesylate

Clinical Trial Phase

Clinical Trial Phase for Saquinavir Mesylate
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status for Saquinavir Mesylate
Clinical Trial Phase	Trials
Completed	7
Withdrawn	1

Clinical Trial Sponsors for Saquinavir Mesylate

Sponsor Name

Sponsor Name for Saquinavir Mesylate
Sponsor	Trials
Hoffmann-La Roche	3
Stanford University	1
AIDS Associated Malignancies Clinical Trials Consortium	1

Sponsor Type

Sponsor Type for Saquinavir Mesylate
Sponsor	Trials
Other	5
Industry	4
NIH	2

Saquinavir Mesylate: Clinical Trials Update, Market Analysis and Projection

Last updated: April 25, 2026

What is saquinavir mesylate and what is its current clinical footprint?

Saquinavir mesylate is an HIV-1 protease inhibitor. It is marketed in multiple countries as saquinavir (formulations include mesylate salt forms). The drug’s modern clinical profile is shaped by (1) long-established use in combination antiretroviral therapy (cART), and (2) competition from once-daily, higher-barrier, and more tolerable regimens that dominate current guideline-based prescribing.

Clinical trials update: active and late-stage development

No complete, current, cross-registry snapshot of ongoing interventional clinical trials for “saquinavir mesylate” alone is reliably derivable from the provided information. Saquinavir-related studies often appear under “saquinavir” (not the mesylate salt) and may be observational, pharmacokinetic (PK), formulation, or historical regimen evaluations rather than new phase-3 efficacy programs.

Result: A verifiable clinical trials update for “saquinavir mesylate” requires registry-level confirmation that is not available in the supplied context; therefore, no trial-level claims can be stated here.

Where does saquinavir mesylate sit in current HIV treatment economics?

Saquinavir-based regimens face structural market headwinds:

• Line-of-therapy displacement: modern guidelines increasingly position newer agents earlier due to convenience, safety, resistance robustness, and simplified dosing.
• Protease inhibitor category pressure: boosted protease inhibitors and non-nucleoside alternatives compete on dosing frequency, drug-drug interaction (DDI) burden, and adverse event profiles.
• Generics and price erosion: saquinavir has faced extensive genericization pressure in many markets over time, reducing the scope for premium pricing absent patent-protected differentiation.

Market structure relevant to projections

A credible market projection must anchor on:

1. Global HIV treated population (diagnosed and on ART)
2. Protease inhibitor share and within-class share for first-generation agents
3. Formulation-specific uptake (saquinavir vs other PIs)
4. Patent and exclusivity status by country
5. Reimbursement patterns and guideline adherence

The supplied context does not include region-specific uptake, tender pricing, or exclusivity status by jurisdiction. Without those inputs, a defensible numeric projection would risk being non-verifiable.

Result: No numerical market forecast (TAM/SAM/SOM, CAGR, or unit volumes) can be presented without registry and market input data tied to saquinavir mesylate specifically.

---

What is the market opportunity baseline for saquinavir mesylate?

Even without numeric projections, the opportunity baseline can be bounded by market mechanics that apply to established HIV agents:

Demand drivers

• Second-line and salvage use in certain clinical settings where protease inhibitors remain viable.
• Treatment experience: clinician familiarity and existing compatibility data in certain patient subsets.
• Access via formularies: national and payer-level inclusion can preserve baseline volumes even when guideline priority shifts.

Demand constraints

• Guideline shift to newer regimens that reduce pill burden and DDI complexity.
• Adherence friction: older dosing schedules can lower real-world persistence versus once-daily combinations.
• Competitive substitution: other boosted PIs and fixed-dose combinations typically displace older monotherapy protease inhibitor usage where possible.

---

What would an actionable market projection require for saquinavir mesylate?

A projection that meets investment-grade standards must include a data spine across these dimensions:

• Geography: US, EU5, UK, Japan, plus major ROW markets
• Formulation: saquinavir mesylate uptake versus other salt forms or saquinavir presentations
• Channel: public procurement versus private retail
• Channel pricing: weighted average net price and expected erosion
• Therapy share: protease inhibitor share and saquinavir share within it
• Policy shocks: generic entry waves and formulary revisions
• Patent calendar: country-by-country expiry and any patent term extensions

The supplied prompt does not include the patent calendar, country market shares, pricing, or current formulary inclusion data for saquinavir mesylate, so any numeric projection would be non-falsifiable.

---

Key Takeaways

• Saquinavir mesylate is an established HIV-1 protease inhibitor whose current clinical and commercial position is dominated by displacement from newer, more convenient regimens.
• A trial-level “clinical trials update” for saquinavir mesylate cannot be stated here without a verifiable registry-level dataset for the mesylate salt (not just “saquinavir” generally).
• A quantified market forecast for saquinavir mesylate cannot be provided from the information in the prompt because region-specific uptake, pricing, exclusivity, and formulary inclusion are not available in the provided context.

FAQs

1. Is saquinavir mesylate still under active phase-3 development?
   Not determinable from the provided context; saquinavir-related studies typically run under “saquinavir” and may not reflect new mesylate-specific phase-3 programs.

2. Does saquinavir mesylate have a meaningful role in current HIV guidelines?
   It can remain relevant in specific clinical circumstances, but guideline priority has shifted toward newer regimens due to convenience and tolerability.

3. What most constrains saquinavir mesylate market growth?
   Generic price erosion, dosing convenience compared with current standards, and substitution within protease inhibitor classes.

4. Can a market projection be made without patent-by-country calendars and current uptake shares?
   No; investment-grade projections require exclusivity and uptake inputs by geography and channel.

5. How should saquinavir mesylate demand be modeled?
   By decomposing global ART population into protease inhibitor share, then saquinavir share within PIs, adjusted for pricing and generic entry timing by region.

---

References

[1] FDA. “Saquinavir” (drug information and labeling resources). US Food and Drug Administration. https://www.fda.gov
[2] European Medicines Agency (EMA). “Invirase” and related product information (saquinavir). European Medicines Agency. https://www.ema.europa.eu
[3] NIH. “Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.” National Institutes of Health. https://clinicalinfo.hiv.gov
[4] World Health Organization (WHO). “Consolidated guidelines for the use of antiretroviral drugs for treating and preventing HIV infection.” WHO. https://www.who.int
[5] ClinicalTrials.gov. “Saquinavir” and related search results (trial listings and statuses). https://clinicaltrials.gov